Cassandra Slader

1.5k total citations · 1 hit paper
20 papers, 1.0k citations indexed

About

Cassandra Slader is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Cassandra Slader has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 12 papers in Hematology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Cassandra Slader's work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Acute Lymphoblastic Leukemia research (5 papers). Cassandra Slader is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Acute Lymphoblastic Leukemia research (5 papers). Cassandra Slader collaborates with scholars based in Australia, Switzerland and New Zealand. Cassandra Slader's co-authors include Timothy P. Hughes, Andrew Grigg, Anthony K. Mills, Robin Filshie, Anthony P. Schwarer, Christopher Arthur, David M. Ross, Susan Branford, John F. Seymour and Deborah L. White and has published in prestigious journals such as Blood, PLoS ONE and Thorax.

In The Last Decade

Cassandra Slader

19 papers receiving 997 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers

Cassandra Slader

HEMAT

GENET

RHEUM

ONCOL

PRM

Eveline de Bont Netherlands

Allison McGee Ireland

Shien Guo United States

R. Rau Germany

Maria Concetta Galati Italy

Beng Fuh United States

Brigitta Rumberger Germany

Vipul N. Mankad United States

Wei‐Sheng Huang Taiwan

Moetaza M. Soliman Egypt

Eveline de Bont Netherlands

Cassandra Slader

227 ×0.3

HEMAT

147 ×0.2

GENET

57 ×0.1

RHEUM

77 ×0.5

ONCOL

47 ×0.4

PRM

Citations per year, relative to Cassandra Slader Cassandra Slader (= 1×) peers Eveline de Bont

Countries citing papers authored by Cassandra Slader

Since Specialization

Citations

This map shows the geographic impact of Cassandra Slader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cassandra Slader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cassandra Slader more than expected).

Fields of papers citing papers by Cassandra Slader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cassandra Slader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cassandra Slader. The network helps show where Cassandra Slader may publish in the future.

Co-authorship network of co-authors of Cassandra Slader

This figure shows the co-authorship network connecting the top 25 collaborators of Cassandra Slader. A scholar is included among the top collaborators of Cassandra Slader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cassandra Slader. Cassandra Slader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Viprakasit, Vip, Mona Hamdy, Hoda Hassab, et al.. (2023). Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia. Annals of Hematology. 102(8). 2039–2049. 4 indexed citations

Slader, Cassandra, et al.. (2021). Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China. PLoS ONE. 16(10). e0259076–e0259076. 2 indexed citations

Turkina, Anna, Jianxiang Wang, Vikram Mathews, et al.. (2020). TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology. 190(6). 869–876. 35 indexed citations

Memon, Muhammad Ali, Burçak Karaca, Mustafa Erman, et al.. (2018). Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON). Journal of Cancer Research and Clinical Oncology. 144(11). 2219–2229. 1 indexed citations

Ross, David M., Susan Branford, John F. Seymour, et al.. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 122(4). 515–522. 508 indexed citations breakdown →

Yeung, David T, Michael Osborn, Deborah L. White, et al.. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Blood. 120(21). 3771–3771. 14 indexed citations

White, Deborah L., Jerald P. Radich, Simona Soverini, et al.. (2011). Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 97(6). 907–914. 44 indexed citations

Kok, Chung Hoow, et al.. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. Blood. 118(21). 1675–1675. 1 indexed citations

White, Deborah L., Verity A Saunders, Amity Frede, et al.. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. Blood. 118(21). 1690–1690. 1 indexed citations

10.

Yeung, David T, Michael Osborn, Deborah L. White, et al.. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. Blood. 118(21). 451–451. 23 indexed citations

11.

Ross, David M., Susan Branford, John F. Seymour, et al.. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 24(10). 1719–1724. 194 indexed citations

12.

White, Deborah L., Verity A Saunders, Amity Frede, et al.. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. Blood. 116(21). 356–356. 3 indexed citations

13.

Osborn, Michael, Deborah L. White, Susan Branford, et al.. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. Blood. 116(21). 209–209. 9 indexed citations

14.

Osborn, Michael, Deborah L. White, Verity A Saunders, et al.. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. Blood. 114(22). 1131–1131. 4 indexed citations

15.

Slader, Cassandra. (2006). Double blind randomised controlled trial of two different breathing techniques in the management of asthma. Thorax. 61(8). 651–656. 64 indexed citations

16.

Slader, Cassandra, Helen K. Reddel, Christine Jenkins, Carol Armour, & Sinthia Bosnic‐Anticevich. (2006). Complementary and alternative medicine use in asthma: Who is using what?. Respirology. 11(4). 373–387. 115 indexed citations

17.

Marks, Guy B., Maxime C. Cohen, Vicki Kotsirilos, et al.. (2005). Asthma and Complementary Therapies: A Guide for Health Professionals. Queensland's institutional digital repository (The University of Queensland). 43(6). 925–30. 4 indexed citations

18.

Slader, Cassandra, Helen K. Reddel, & Sinthia Bosnic‐Anticevich. (2004). Lack of Awareness of Need to Clean CFC‐Free Metered‐Dose Inhalers. Journal of Asthma. 41(3). 367–373. 5 indexed citations

19.

Slader, Cassandra & Susan Welch. (2003). Audit of Celecoxib and Rofecoxib Use: St Vincent's Public Hospital, Darlinghurst. Journal of Pharmacy Practice and Research. 33(1). 74–77.

20.

Bennett, Alexandra & Cassandra Slader. (2003). Perceived Barriers by Hospital Pharmacists to Become Accredited to Perform Medication Reviews in the Home. Journal of Pharmacy Practice and Research. 33(3). 183–185. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact